Discounted Cash Flow
Astrazeneca Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $23.0b | $3.5b | $2.7b | 15.2% | $2.77 |
| 2017 | $22.5b (-2.3%) | $3.0b (-14.2%) | $2.3b (-16.6%) | 13.4% (-12.2%) | $2.37 (-14.4%) |
| 2018 | $22.1b (-1.7%) | $2.2b (-28.2%) | $1.6b (-30.1%) | 9.8% (-27.0%) | $1.70 (-28.3%) |
| 2019 | $24.4b (10.4%) | $1.3b (-38.1%) | $2.0b (26.3%) | 5.5% (-43.9%) | $1.03 (-39.4%) |
| 2020 | $26.6b (9.2%) | $3.2b (139.4%) | $3.8b (92.9%) | 12.0% (119.3%) | $2.44 (136.9%) |
| 2021 | $37.4b (40.6%) | $112.0m (-96.5%) | $5.8b (51.5%) | 0.3% (-97.5%) | $0.08 (-96.7%) |
| 2022 | $44.4b (18.5%) | $3.3b (2835.7%) | $7.2b (24.5%) | 7.4% (2376.7%) | $2.12 (2550.0%) |
| 2023 | $45.8b (3.3%) | $6.0b (81.1%) | $6.6b (-9.3%) | 13.0% (75.3%) | $3.84 (81.1%) |
| 2024 | $54.1b (18.0%) | $7.0b (18.1%) | $7.3b (10.8%) | 13.0% (0.1%) | $4.54 (18.2%) |
| 2025 | $58.7b (8.6%) | $10.2b (45.3%) | $8.7b (19.2%) | 17.4% (33.8%) | $6.60 (45.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.